<DOC>
	<DOCNO>NCT00508547</DOCNO>
	<brief_summary>The purpose study evaluate safety infliximab ustekinumab patient plaque psoriasis , form psoriasis ( plaque psoriasis psoriatic arthritis occur together ) . The registry study track behavior disease response therapy , biologic drug . The registry also evaluate clinical outcome ; disease characteristic , include physician report assessment psoriatic arthritis ( PsA ) ; quality life , potential risk patient may receive standard therapy psoriasis .</brief_summary>
	<brief_title>Psoriasis Longitudinal Assessment Registry ( PSOLAR )</brief_title>
	<detailed_description>PSOLAR 8 year registry study . A registry observational study evaluate status disease . This registry study include patient volunteer take part . About 2000 infliximab-exposed patient 4000 ustekinumab-exposed patient well comparable number patient ( 4000 ) standard care psoriasis therapy ( e.g . Etanercept ) and/or psoriasis treatment ( e.g . topical light therapy treatment ) take part registry study , internationally . The Registry require study-specific testing , may capture test information ( e.g . laboratory test , X-rays ) collect part normal routine care registry program . Patient information collect enrollment visit every 6 month thereafter . At enrollment , information demographic ( e.g . gender , race , date birth ) , medical history family medical history , detail past current psoriasis treatment ( e.g . infliximab standard therapy ) , current medication regimen collect . Clinical follow-up base observation physical examination , clinical disease status , Quality Life assessment ( e.g . Dermatology Life Quality Index , Hospital Anxiety Depression Scale , EQ-5D ( EuroQoL-5D Quality Life Questionnaire ) Health Questionnaire Scale , Employment/Productivity Health Economic Questionnaire ) , current medication , adverse events/problems report . During six -month follow-up visit study doctor , information collect include observation physical examination , update clinical disease status , Quality life assessment , medication adverse events/problems . No study agent administer registry . All patient receive standard care treatment prescribe patient 's physician .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Have diagnosis psoriasis Are candidate , currently receive conventional systemic agent ( eg , methotrexate , acitretin , cyclosporine systemic psoralen drug combination Ultraviolet A light [ PUVA ] ) biologic therapy psoriasis include chronic severe ( extensive and/or disable ) plaque psoriasis may treat infliximab Ability understand sign inform consent form Are willing participate regular followup visit Refuse consent unwilling respond request long term information within required time frame Are participate already plan participate clinical trial nonmarketed investigational agent participate Centocorsponsored clinical trial market agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Methotrexate</keyword>
	<keyword>Acitretin</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Systemic PUVA</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Alefacept</keyword>
	<keyword>Efalizumab</keyword>
	<keyword>Etanercept</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Psoriatic arthritis</keyword>
	<keyword>Skin disease</keyword>
	<keyword>Cosentyx</keyword>
</DOC>